Gilead present new BIKTARVY®▼ (bictegravir / emtricitabine / tenofovir alafenamide) data at IAS 2019

The 10th International AIDS Society (IAS) conference was held in Mexico City from 21-24 July 2019. Results from two BIKTARVY® studies, involving more than 500 people living with HIV (PLHIV) were presented.1,2 Key outcomes and clinical implications from each study are discussed below.